The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter.
Antoine Angelergues
No relevant relationships to disclose
Denis Maillet
No relevant relationships to disclose
Aude Flechon
Honoraria - Sanofi
Mustafa Ozguroglu
No relevant relationships to disclose
Florence Mercier
Consultant or Advisory Role - Boston Scientific; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Sanofi
Aline Guillot
No relevant relationships to disclose
Sylvestre Le Moulec
No relevant relationships to disclose
Gwenaelle Gravis
Consultant or Advisory Role - Sanofi (U)
Philippe Beuzeboc
Honoraria - Sanofi
Christophe Massard
No relevant relationships to disclose
Thibault De La Motte Rouge
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Research Funding - Astellas Pharma; Millennium
Reza-Thierry Elaidi
No relevant relationships to disclose
Stephane Oudard
Consultant or Advisory Role - Amgen; Bayer; Keocyt; Novartis; Roche; Sanofi
Honoraria - Amgen; Bayer; Keocyt; Novartis; Pfizer; Roche; Sanofi